Intrexon | XON - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
Agenus USD 6.21M 4.34M 2026-03
Alaunos Therapeutics USD 447K 138K 2026-03
Amgen USD 1.72B 134M 2026-06
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.63M 4.88M 2026-06
AstraZeneca USD 5.8B 735M 2026-06
Bristol-Myers Squibb USD 1.83B 209M 2026-06
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.19B 75M 2026-06
Heron Therapeutics USD 23.74M 605K 2025-12
Incyte USD 351.73M 23.64M 2026-06
Intrexon USD 10.31M 41K 2024-06
Karyopharm Therapeutics USD 10.42M 861K 2026-03
Ligand Pharmaceuticals USD 29.12M 8.29M 2026-06
MacroGenics USD 9.71M 1.77M 2026-03
MannKind USD 58.3M 4.22M 2026-06
Merck USD 2.89B 219M 2026-06
Novartis USD 3.24B 101M 2026-06
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Roche Holding CHF 6.37B 908M 2026-06
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Thermo Fisher Scientific USD 1.91B 111M 2026-06
Veracyte USD 55.71M 4.87M 2026-06
Xencor USD 77.54M 4.59M 2026-06